Patients receiving first-line systemic treatment with a BRAF mutation had a higher risk for shorter survival in multivariable analysis, although nonsignificant, which is reflected with an 8-month difference in the unadjusted median OS in patients with a BRAF mutant versus BRAF-wildtype tumour. The gene discussed is BRAF; the disease is neoplasm.